Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 16/20 | 0.45 |
| ▸ | JAK2 | O60674 | 15/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28371220 | 1.00 | NTRK1 (0.45) | NTRK1JAK2JAK1CYP1A2POLB | |
| SCHEMBL30036711 | 1.00 | NTRK1 (0.45) | NTRK1JAK2JAK1CYP1A2POLB | |
| SCHEMBL29977880 | 1.00 | NTRK1 (0.45) | NTRK1JAK2JAK1CYP1A2POLB | |
| SCHEMBL23070666 | 1.00 | NTRK1 (0.45) | NTRK1JAK2JAK1CYP1A2POLB | |
| SCHEMBL30480051 | 1.00 | NTRK1 (0.45) | NTRK1JAK2JAK1CYP1A2POLB | |
| SCHEMBL23070651 | 1.00 | NTRK1 (0.45) | NTRK1JAK2JAK1CYP1A2POLB | |
| SCHEMBL30480054 | 1.00 | NTRK1 (0.45) | NTRK1JAK2JAK1CYP1A2POLB | |
| SCHEMBL28621956 | 1.00 | NTRK1 (0.45) | NTRK1JAK2JAK1CYP1A2POLB | |
| SCHEMBL29977249 | 1.00 | NTRK1 (0.45) | NTRK1JAK2JAK1CYP1A2POLB | |
| SCHEMBL23070665 | 0.89 | NTRK1 (0.42) | NTRK1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4329766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022231928-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228506-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | NTRK1 1304/4885JAK2 1321/4885JAK1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.